SCHEMBL21708013

SCHEMBL21708013

CCOC(=O)c1csc(Nc2cc(F)ccc2F)n1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.67
LMNA P02545 4/20 0.67
KDM4E B2RXH2 3/20 0.67
TDP1 Q9NUW8 2/20 0.67
NPSR1 Q6W5P4 2/20 0.67
CYP1A2 P05177 1/20 0.54
CYP2C19 P33261 1/20 0.54
SMN1; SMN2 Q16637 6/20 0.52
RAB9A P51151 5/20 0.52
NPC1 O15118 4/20 0.52
GAA P10253 2/20 0.52
L3MBTL1 Q9Y468 1/20 0.51
EGFR P00533 1/20 0.50
HSD17B10 Q99714 1/20 0.49
MAPK1 P28482 2/20 0.49
HSP90AA1 P07900 2/20 0.49
ALDH1A1 P00352 2/20 0.48
ANO1 Q5XXA6 1/20 0.48
HPGD P15428 1/20 0.47
TSHR P16473 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21708015 0.91 MAPT (0.67) MAPTLMNAKDM4ETDP1NPSR1
SCHEMBL790034 0.86 SMN1; SMN2 (0.60) MAPTLMNAKDM4ETDP1NPSR1
SCHEMBL10464406 0.83 MAPT (0.65) MAPTLMNAKDM4ETDP1NPSR1
SCHEMBL19667963 0.81 MAPT (0.62) MAPTLMNAKDM4ETDP1NPSR1
SCHEMBL4722539 0.78 L3MBTL1 (0.58) MAPTLMNAKDM4ETDP1NPSR1
SCHEMBL10464759 0.78 RAB9A (0.62) MAPTLMNAKDM4ETDP1NPSR1
SCHEMBL21708009 0.77 CYP1A2 (0.54) MAPTLMNAKDM4ETDP1NPSR1
SCHEMBL31436988 0.77 CYP1A2 (0.54) MAPTLMNAKDM4ETDP1NPSR1
Bromide SCHEMBL10669503 0.77 CYP1A2 (0.54) MAPTLMNAKDM4ETDP1NPSR1
SCHEMBL15349192 0.77 CYP1A2 (0.54) MAPTLMNAKDM4ETDP1NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200062719-A1 Application of Imidazopyridine Derivatives in Regenerative Medicine UNIVERSITY OF HEIDELBERG (DE) 2020-02-27 US disclosed
EP-3611256-A1 APPLICATION OF IMIDAZOPYRIDINE DERIVATIVES IN REGENERATIVE MEDICINE Universität Heidelberg (DE) 2020-02-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200062719-A1 Application of Imidazopyridine Derivatives in Regenerative Medicine DOT1L, NSD1, KDM3A MAPT 4560/4885LMNA 3592/4885KDM4E 42/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.